Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 11:35 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1177–1200 of 3,156 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Combination Intervention Clear all

Conditions: Communication, Anxiety, Depression, Social Isolation
Interventions: Asynchronous coaching and artificial intelligence (AI) Yoodli coach sessions; Behavioral
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 18 Years to 35 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Hershey, Pennsylvania

Conditions: Breast Cancer
Interventions: Inavolisib, Fulvestrant, Alpelisib, Bupropion, Omeprazole, Midazolam; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 420 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 39
States / cities: Greenbrae, California • Los Alamitos, California • Los Angeles, California + 32 more

Conditions: Borderline Resectable Pancreatic Ductal Adenocarcinoma, Locally Advanced Cholangiocarcinoma, Locally Advanced Pancreatic Adenocarcinoma, Metastatic Cholangiocarcinoma, Metastatic Pancreatic Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8
Interventions: Biopsy Procedure, Cisplatin, Computed Tomography, Durvalumab, Fluorouracil, Gemcitabine, Irinotecan, Leucovorin, Ligritinib, Magnetic Resonance Imaging, Oxaliplatin, Zimberelimab; Procedure · Drug · Biological
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Low Back Pain
Interventions: yoga, pain education, yoga nidra, yoga, pain education, relaxing music; Other
Lead sponsor: University of Central Florida; Other
Eligibility: 18 Years to 75 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Gastric Cancer, Stomach Cancer
Interventions: Cetuximab, Irinotecan, Cisplatin, Surgery, 5-FU, Radiation; Drug · Procedure · Radiation
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2015
U.S. locations: 1
States / cities: New York, New York

Conditions: Smoking, Smoking Cessation, Adherence, Nicotine Dependence, Motivation
Interventions: Short Term Combination Nicotine Replacement Therapy (patch + gum), Long Term Combination Nicotine Replacement Therapy (patch + gum), Intensive Maintenance Counseling, Cognitive Medication Adherence Counseling (CAM), Electronic Medication Monitoring Device (the Helping Hand) + Feedback, Automated Adherence Prompting Phone Calls; Drug · Behavioral
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years to 99 Years
Enrollment: 544 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Leukoplakia, Erythroplakia
Interventions: PDL-585, ScleroPLUS laser, 5-Aminolevulinic Acid (Levulan KerastickTM), Fluorescence Diagnosis Imaging; Device · Drug · Procedure
Lead sponsor: University of Arkansas; Other
Eligibility: 18 Years to 80 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Asthma, Lung Diseases
Interventions: Facilitated Asthma Communication Intervention (FACI), Breathmobile intervention; Behavioral
Lead sponsor: Johns Hopkins University; Other
Eligibility: 2 Years to 6 Years
Enrollment: 336 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Autism Spectrum Disorder
Interventions: Jasper, Parent Education; Behavioral
Lead sponsor: Boston University Charles River Campus; Other
Eligibility: 18 Months to 59 Months
Enrollment: 89 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Hepatocellular Carcinoma, Cirrhosis, Portal Hypertension
Interventions: Durvalumab, Tremelimumab, Liver Transplant; Drug · Procedure
Lead sponsor: University of Cincinnati; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 3
States / cities: St Louis, Missouri • Cincinnati, Ohio • Dallas, Texas

Conditions: HIV Prevention, Sexually Transmitted Diseases, Pre-Exposure Prophylaxis
Interventions: HOME Study intervention, Control; Behavioral
Lead sponsor: Public Health Foundation Enterprises, Inc.; Other
Eligibility: 18 Years to 35 Years · Male only
Enrollment: 104 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Pancreatic Cancer
Interventions: Oxaliplatin, 5FU, Radiation, Surgery, FOLFOX 6; Drug · Radiation · Procedure
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2015
U.S. locations: 2
States / cities: New York, New York

Conditions: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: PET/CT scan, 18F-FDG Injection, Preoperative 18F-FDG PET/CT Scan, 18F-FDG for patients with Bladder Cancer, Surgical Procedure, Specimen PET/CT Scan; Procedure · Drug
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Hodgkin Lymphoma
Interventions: Biospecimen Collection, Computed Tomography, Decitabine and Cedazuridine, Nivolumab, Positron Emission Tomography; Procedure · Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 9
States / cities: Birmingham, Alabama • Duarte, California • Sacramento, California + 6 more

Conditions: Anemia, Decreased Glomerular Filtration Rate
Interventions: Enhanced diagnostic team implementing three evidence-based interventions, Usual care; Other
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years and older
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Metastatic Pancreatic Cancer, Metastatic Pancreatic Adenocarcinoma
Interventions: Gemcitabine combined with nab-paclitaxel, Dose -mFOLFIRINOX, Dose - Pamrevlumab combined with gemcitabine and nab-paclitaxel, Dose- Canakinumab and Spartalizumab combined with nab-paclitaxel and gemcitabine, Drug: Dose -SM-88; Drug
Lead sponsor: Pancreatic Cancer Action Network; Other
Eligibility: 18 Years and older
Enrollment: 502 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 25
States / cities: La Jolla, California • Los Angeles, California • San Francisco, California + 18 more

Conditions: Metabolic Syndrome
Interventions: High Protein Diet, Exercise; Behavioral
Lead sponsor: University of Georgia; Other
Eligibility: 50 Years to 64 Years · Female only
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Athens, Georgia

Conditions: Dementia, Alzheimer Type, Problem Behavior
Interventions: Door cover/Floor cover; Device
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: 60 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: HIV-1 Infection
Interventions: Vorinostat, HXTC; Drug · Biological
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 64 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Failed Labour
Interventions: Prepidil Gel, Urinary Balloon Catheter, Combined Urinary Catheter & Prepidil Gel; Drug · Device · Other
Lead sponsor: University of South Carolina; Other
Eligibility: 18 Years and older · Female only
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Columbia, South Carolina

Conditions: Esophageal Cancer
Interventions: cisplatin, fluorouracil, paclitaxel, surgical procedure, radiation therapy; Drug · Procedure · Radiation
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2007
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Chronic Kidney Diseases, Hyperkalemia
Interventions: Sodium Zirconium Cyclosilicate Oral Product; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 80 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Binocular Vision Disorder, Refractive Errors, Cataract
Interventions: cataract surgery, Corneal refractive surgery; Procedure
Lead sponsor: Salus University; Other
Eligibility: 18 Years and older
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 1
States / cities: Elkins Park, Pennsylvania

Conditions: Pancreatic Ductal Adenocarcinoma (PDAC)
Interventions: Endoscopic Ultrasound (EUS)-Guided Radiofrequency Ablation (RFA), Neoadjuvant Chemotherapy (NAC); Device · Drug
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 1
States / cities: Houston, Texas

Search by objective public record fields.

AYA-PeerConnect: A Communication Coaching Intervention for Adolescent/Young Adult Cancer Survivors (AYACS)

A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy

AB801 in Combination With Chemotherapy and Immunotherapy for the Treatment of Patients With Borderline Resectable, Locally Advanced or Metastatic Cholangiocarcinoma or Pancreatic Cancer

Yoga, Education, and Nidra (YEN) for Chronic Low Back Pain: A Pilot Study on Pain Modulation, Well-Being, and Sleep

Pre-operation Chemo and Antibody Therapy Followed by Surgical Resection and Adjuvant Chemoradiation for Gastric Cancer

Evaluation of Treatments to Improve Smoking Cessation Medication Adherence

Treatment of Oral Premalignant Lesions With 5-ALA PDT

Intervention for Improving Asthma Care for Minority Children in Head Start

Training Early Social Language in Autism

Durvalumab (MEDI4736) and Tremelimumab for Hepatocellular Carcinoma in Patients Listed for a Liver Transplant

HOME Study: a Combination Support Package to Increase Uptake of PrEP and HIV/STI Testing

Chemoradiation With Oxaliplatin and Fluorouracil (5FU) for Locally Advanced Pancreatic Cancer

Fludeoxyglucose F 18 PET/CT Imaging in Finding Cancer in Patients Undergoing Surgery for Solid Tumors

Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma

A New Combination of Evidence-Based Interventions to Improve Primary Care Diagnostic Safety and Efficiency

A Multi-center Trial to Evaluate Multiple Regimens in Metastatic Pancreatic Cancer

Exercise-Induced Epigenetic Modifications in Obese Aging Women

Home Evaluation of Exit Barriers in Wandering

Study to Evaluate Effects of Vorinostat and HXTC on Persistent HIV-1 Infection in HIV-Infected Subjects Started on Antiretroviral Therapy (ART)

Comparison of Pre-Induction Cervical Ripening

Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Advanced or Metastatic Cancer of the Esophagus

Potassium Binder in CKD Patients (With Hyperkalemia) (DiPo Trial)

Binocular Vision Anomalies After Cataract and Refractive Surgery

EUS-RFA PANCARDINAL-1 Trial